論文種別 原著(症例報告除く)
言語種別 英語
査読の有無 その他(不明)
表題 A LAT1-selective PET tracer, 5-[¹⁸F]F-αMe-3BPA, as a companion to its structurally matched ¹⁰B analog in boron neutron capture therapy.
掲載誌名 正式名:European journal of nuclear medicine and molecular imaging
略  称:Eur J Nucl Med Mol Imaging
ISSNコード:16197089/16197070
掲載区分国外
巻・号・頁 pp.Online ahead of print
著者・共著者 Naoya Kondo, Fuko Hirano, Yasukazu Kanai, Kensuke Suzuki, Anna Miyazaki, Takashi Temma
発行年月 2025/11
概要 PURPOSE:This study aimed to develop and evaluate 5-[¹⁸F]F-αMe-3BPA, a novel PET probe designed as a theranostic partner for 5F-αMe-3[¹⁰B]BPA in Boron Neutron Capture Therapy (BNCT). The goal was to address limitations of the clinically used BPA/[¹⁸F]FBPA pair, including poor water solubility, limited LAT1 specificity, and suboptimal diagnostic performance, thereby improving tumor-selective drug delivery and enabling accurate prediction of therapeutic biodistribution through structure-matched PET/BNCT.METHODS:LAT1 dependency was tested in vitro using cancer cell lines with differential LAT1 expression. In vivo biodistribution of both therapeutic agents and their ¹⁸F-labeled analogs were assessed in xenograft mouse models. Radiosynthesis of 5-[¹⁸F]F-αMe-3BPA was achieved via copper-catalyzed nucleophilic radiofluorination. PET/CT imaging compared tumor visualization with [¹⁸F]FBPA. Co-injection studies (5-[¹⁸F]F-αMe-3BPA/5F-αMe-3BPA and [¹⁸F]FBPA/BPA) quantitatively evaluated concordance between ¹⁸F radioactivity and boron concentrations across tissues.RESULTS:5F-αMe-3BPA uptake in cancer cells was strictly LAT1-dependent. In LAT1-high T3M-4 xenografts, its tumor-to-muscle boron ratio (22) far exceeded BPA (3.4). 5-[¹⁸F]F-αMe-3BPA was synthesized successfully and achieved a tumor-to-muscle ratio of 29 versus 5.3 for [¹⁸F]FBPA. PET imaging showed clear, high-contrast visualization of T3M-4 tumors, with co-injection confirming strong concordance between PET probe and therapeutic agent biodistribution.CONCLUSION:The 5-[¹⁸F]F-αMe-3BPA/5F-αMe-3[¹⁰B]BPA theranostic pair demonstrates high LAT1 specificity, low normal tissue uptake, and strong pharmacokinetic alignment, enabling accurate prediction of therapeutic boron delivery for BNCT. Furthermore, 5-[¹⁸F]F-αMe-3BPA shows promise as a dedicated LAT1 imaging probe for advancing LAT1-targeted therapies.
DOI 10.1007/s00259-025-07668-3
PMID 41251747